HURA TuHURA Biosciences, Inc.: Sof marja

TuHURA Biosciences, Inc. (HURA) tovar belgisi

TuHURA Biosciences, Inc. (HURA) FDA qo'llab-quvvatlovi ostida innovatsion saraton vaksinalari ekotizimini ishlab chiqmoqda, bu esa hamkorlarning doimiy ravishda jalb qilinishiga olib kelmoqda. Sof operatsion marja ushbu muvaffaqiyatlarni aks ettiradi va 0.00 belgisi ushbu metrikani qamrab oladi. Biroq, yuqori R&D xarajatlari va qat'iy tartibga soluvchi nazorat sezilarli to'siqlarni yuzaga keltirmoqda. O'simta muhitini modifikatsiya qilishga oid patentlarning murakkabligi ulkan investitsiyalarni talab etadi, bu esa ushbu nishaga kirish imkoniyatlarini cheklaydi.

TuHURA Biosciences Inc. (HURA) - Sotuvning sof marjinal rentabelligi 04.07.2022dan 20.11.2026gacha

tuhurabio.com (HURA) moliyaviy va bozor koʻrsatkichlari kesimi

- aksiya narxi va baholash bo'yicha konsensus prognoz:
Kompaniyaning barcha koʻrsatkichlari tahlili:TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. yetakchi tovari

Yuqori sifatli aktivlarni saralash uchun investorlar daromadning sof foydaga aylanish samaradorligini baholashi va beqaror operatsion modellarga ega kompaniyalarni chiqarib tashlashi lozim. Ushbu marja profili barcha xarajatlardan keyingi yakuniy foyda ulushini o'lchaydi, bu esa vaksinalarning klinik sinovlari uchun yuqori kapital sarfi va daromadlilikning innovatsion ishlanmalar muvaffaqiyatiga bog'liqligi sababli TuHURA Biosciences, Inc. (HURA) uchun juda muhimdir.

Raqobatdosh kompaniyalar tahlili

ONC: Sotuvning sof marjinal rentabelligi|Sof marja Halozyme Inc. (HALO)|Sof marja RevMed|Sotuvning sof rentabelligi AAPG (Ascentage Pharma Group)|Sotuvning sof marjinal rentabelligi CGON|UroGen Pharma - Sotuvning sof rentabelligi|Bicara Therapeutics - Sof foyda bo'yicha sotuv rentabelligi|Sotuvning sof marjinal rentabelligi Personalis Inc PSNL|Erasca Oncology - Sotuvning sof marjinal rentabelligi|Sof foyda normasi DCTH (Delcath Corp)|YMAB: Sotuvning sof marjinal rentabelligi|AURA - Kompaniya sotuv marjasi|CADL (Candel Therapeutics Inc.) - Sotuvning sof marjinal rentabelligi|Sotuvning sof rentabelligi ARAY (Accuray)|Sof foyda bo'yicha sotuv rentabelligi SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Sof marja|Sof marja Citius Oncology, Inc. CTOR|Sof foyda normasi TARA|FATE: Sof foyda bo'yicha sotuv rentabelligi|WHWK (aadibio.com) - Sotuvning sof rentabelligi|TCRX (TScan Therapeutics, Inc.) - Sof foyda bo'yicha sotuv rentabelligi|Sof marja Champions Oncology Corp (CSBR)|XBIT (XBiotech Inc.) - Sotuvning sof marjinal rentabelligi|CVM (CEL-SCI Corporation) - Kompaniyaning sof rentabelligi|Sotuvning sof marjinal rentabelligi OSTX|Sotuvning sof marjinal rentabelligi Radiopharm Theranostics Ltd (RADX)|Sotuvning sof marjinal rentabelligi ARTV (Artiva Biotherapeutics)|Sotuvning sof marjinal rentabelligi Adlai Nortye Ltd. ANL|Veru Inc - Sotuvning sof marjinal rentabelligi|Kompaniya sotuv marjasi Tempest Therapeutics TPST|XLO: Sotuvning sof marjinal rentabelligi|Enochian BioSciences (RENB) - Sotuvning sof marjinal rentabelligi|Sof foyda bo'yicha sotuv rentabelligi MURA|Kairos Pharma Ltd - Sof foyda marjasi|Sotuvning sof marjinal rentabelligi OKUR|CytoMed Therapeutics Limited (GDTC) - Sof foyda bo'yicha marjinallik|Sotuvning sof marjinal rentabelligi CRIS (Curis, Inc.)|APLM: Sotuvning sof rentabelligi|Tharimmune Corporation - Sotuvning sof marjinal rentabelligi|ADVB: Sof marja|GNPX: Sotuvning sof marjinal rentabelligi|CLDI (Calidi Biotherapeutics Inc.) - Sof marja|Sof marja Sunshine Biopharma, Inc.|Sotuvning sof marjinal rentabelligi xeneticbio.com|Sof marja Salarius (SLRX)|Sof foyda bo'yicha sotuv rentabelligi Purple Biotech PPBT|Sof marja American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Sof marja|Checkpoint Therapeutics Inc. - Sotuvning sof marjinal rentabelligi|Sof foyda normasi ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Sof foyda bo'yicha sotuv rentabelligi|Ikena Oncology, Inc. - Sof foyda normasi|Sof foyda bo'yicha sotuv rentabelligi NTBL|VIRX: Sof foyda normasi|Sof marja MorphoSys Corporation (MOR)|NAYA - Sof marja|Sotuvning sof marjinal rentabelligi AAPGV (Ascentage)